Skip to main content

Anika Therapeutics, Inc.

corporate_fare Company Profile

Anika Therapeutics, Inc.

ANIK·NASDAQ·Industrial Applications And Services·CIK 0000898437

Anika Therapeutics, Inc. is a global leader in OA Pain Management and regenerative solutions, focusing on early intervention orthopedics. Founded in 1992, the company uses its proprietary hyaluronic acid (HA) technology to develop differentiated products. Anika's mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide, driven by partnerships with physicians. In October 2024, Anika announced a strategic shift to concentrate on its OA Pain Management and Regenerative Solutions portfolios. This involved the sale of Arthrosurface Incorporated on October 31, 2024, and the sale of Parcus Medical, LLC on March 7, 2025. Both entities were acquired in early 2020. The company's focused strategy emphasizes HA-based products to address unmet needs in growing markets. Anika is particularly focused on the commercial execution and adoption of its newest product in the Regenerative Solutions portfolio, the Integrity Implant System ("Integrity"). Integrity is an HA-based scaffold designed for rotator cuff and other tendon repairs, and has shown strong performance with continued growth in surgeries and significant adoption by new customers. Anika plans to continue investing in its Regenerative Solutions R&D pipeline in preparation for potential U.S. approval and launch of Hyalofast and Cingal, each representing an incremental U.S. addressable market of at least $1 billion.

Anika Therapeutics, Inc. (NASDAQ:ANIK) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 16 items for ANIK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ANIK spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Anika 10-Q: Q3 Revenue $30.6M; FDA Deems Hyalofast PMA Not Approvable
  • Anika Lifts Low End of Full-Year Revenue Guidance
  • Anika Beats on Revenue Growth, Raises EBITDA Outlook Despite Hyalofast FDA Rejection
  • Anika Therapeutics Swings to Q2 Profit on 16% Revenue Jump, Margin Expansion
  • Record Q2 propels Anika Therapeutics to raise 2026 guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$112.82M
Net Income
-$10.88M
Diluted EPS
-$0.76
Op. Cash Flow
$11.19M
Free Cash Flow
$4.36M
Gross Profit
$63.81M
Operating Income
-$11.05M
Cash & Equivalents
$57.48M
Debt / Equity
0.00×
Net Margin
-9.6%
Shares Outstanding
13.89M sh
Source: 10-K · filed 2026-03-02 · accession 0001171843-26-001275

Short Interest & Short Volume

3.13 days to cover

FINRA reported short interest of 323,508 shares in ANIK as of the October 30, 2026 settlement, a 11.5% decrease from the prior period — about 3.1 days to cover at its recent average daily volume. On November 20, 2026, 58.6% of ANIK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)323,508 shares as of October 30, 2026
Change vs prior period▼ 11.5%
Days to cover3.13 at avg daily volume of 103,489
Daily short volume (FINRA facilities)58.6% of 28,226 shares on November 20, 2026
5-day average short volume56.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$13.23
52-week range · as of 2026-11-06 $9.01 – $22.88
Market cap
$177.22M
Volume
166.5K (1.4× avg)
3-mo avg 121.2K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANIK - Latest Insights

ANIK
Nov 06, 2026, 2:51 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.62
Real-time Price: $13.23 info
Change: -$1.39 (-10%) info
Market Cap: $177.22M info
ANIK
Nov 06, 2026, 7:06 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.81
Real-time Price: $13.23 info
Change: -$5.58 (-30%) info
Market Cap: $177.22M info
ANIK
Nov 06, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.81
Real-time Price: $13.23 info
Change: -$5.58 (-30%) info
Market Cap: $177.22M info
ANIK
Jul 29, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.49
Real-time Price: $13.23 info
Change: -$3.26 (-20%) info
Market Cap: $177.22M info
ANIK
Jul 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.50
Real-time Price: $13.23 info
Change: -$2.27 (-15%) info
Market Cap: $177.22M info
ANIK
Jun 23, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $13.23 info
Change: -$1.36 (-9%) info
Market Cap: $177.22M info
ANIK
Jun 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $13.23 info
Change: -$1.36 (-9%) info
Market Cap: $177.22M info
ANIK
Jun 08, 2026, 9:25 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $14.48
Real-time Price: $13.23 info
Change: -$1.25 (-9%) info
Market Cap: $177.22M info
ANIK
Jun 01, 2026, 11:12 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $13.98
Real-time Price: $13.23 info
Change: -$0.745 (-5%) info
Market Cap: $177.22M info
ANIK
Apr 29, 2026, 7:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.39
Real-time Price: $13.23 info
Change: +$0.840 (+7%) info
Market Cap: $177.22M info
ANIK
Apr 29, 2026, 7:22 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.26
Real-time Price: $13.23 info
Change: -$2.03 (-13%) info
Market Cap: $177.22M info
ANIK
Apr 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.26
Real-time Price: $13.23 info
Change: -$2.03 (-13%) info
Market Cap: $177.22M info
ANIK
Apr 28, 2026, 4:47 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $15.26
Real-time Price: $13.23 info
Change: -$2.03 (-13%) info
Market Cap: $177.22M info
ANIK
Feb 26, 2026, 7:18 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.73
Real-time Price: $13.23 info
Change: +$1.50 (+13%) info
Market Cap: $177.22M info
ANIK
Jan 27, 2026, 7:29 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $9.15
Real-time Price: $13.23 info
Change: +$4.08 (+45%) info
Market Cap: $177.22M info
ANIK
Jan 08, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.55
Real-time Price: $13.23 info
Change: +$3.68 (+39%) info
Market Cap: $177.22M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets